TP53 and myelodysplastic syndrome: Key changes include reduced emphasis on bone marrow blast percentage in defining MDS subtypes, alongside the introduction of two genetically defined entities characterized by SF3B1 mutations (replacing the previous category of MDSs with ring sideroblasts and partially merging unilinear and multilinear dysplasia subtypes) and biallelic TP53 mutations.